Cited by 297Vagus Nerve Stimulation ResearchNeurological disorders and treatmentsTreatment of Major Depression

Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder: a nonrandomized controlled pilot study

Open access
Rong, Peijing, Liu, Jun, Wang, Liping, Liu, Rupeng, Fang, Jiliang, Zhao, Jingjun, Zhao, Yufeng, Wang, Honghong +8 more·2016·Journal of Affective Disorders

Abstract

Background Depression presents a significant burden to both patients and society. One treatment that has emerged is vagus nerve stimulation (VNS), an FDA-approved physical treatment for depressive disorders. However, the application of this intervention has been limited by the involvement of surgery and potential side effects. The aim of this study is to explore the effectiveness of stimulating the superficial branches of the vagus nerve as a solo treatment for MDD.Methods This is a nonrandomized, controlled study. The first cohort of patients (n=91) only received transcutaneous auricular VNS (taVNS) for 12 weeks. In the second cohort (n=69), patients first received 4 weeks of sham taVNS followed by 8 weeks of taVNS. All treatments were self-administered by the patients at home after they received training from the hospitals. The primary outcome measurement was the 24-item Hamilton Depression Rating Scale measured at weeks 0, 4, 8, and 12. Data analysis included a timelag analysis comparing (1) real and sham taVNS groups at week 4; (2) the real taVNS group at week 4 vs the sham taVNS group at week 8 (fourth week of real taVNS following 4 weeks of sham); and (3) the real taVNS group at week 8 vs the sham taVNS group at week 12 (eighth week of real taVNS following sham).Results After four weeks of treatment, MDD patients in the taVNS group showed greater improvement than patients in the sham taVNS group as indicated by Hamilton score changes as well as response and remission rates at week four. In addition, we also found that the clinical improvements continued until week 12 during taVNS.Limitations Patients were not randomized in this study.Conclusions Our results suggest that taVNS is a promising, safe, and cost-effective therapeutic method for mild and moderate MDD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jad.2016.02.031

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rong, P., Liu, J., Wang, L., Liu, R., Fang, J., Zhao, J., Zhao, Y., Wang, H., Vangel, M., Sun, S., Ben, H., Park, J., Li, S., Meng, H., Zhu, B., & Kong, J.
Affiliations
  • China Academy of Chinese Medical Sciences (CN)
  • Beijing University of Chinese Medicine (CN)
  • Harvard University (US)
Corresponding author
  • Rong, Peijing
  • Kong, Jian
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2016-05
Volume
195
Pages
172-179
ISSN
0165-0327 (ISSN-L)
OpenAlex
W2270807063
Cited by
297
References
43
Citations by year
2026: 36 · 2025: 41 · 2024: 42 · 2023: 32 · 2022: 31 · 2021: 41 · 2020: 24 · 2019: 13 · 2018: 16 · 2017: 14 · 2016: 7
FWCI
9.13
Type
journal article
Language
en
Open access
Locations
  • Journal of Affective Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Chinese Medicine of the National Basic Research Program of China (2012CB518503)
  • National Science and Technology Support Program of China (2012BAF14B10)
  • Beijing Natural Science Foundation of China (7111007)
  • NCCIH/NIH (R01AT006364, R01AT008563, R21AT008707, P01 AT006663)
Topics
  • Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
  • Health Sciences › Medicine › Neurology › Neurological disorders and treatments
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
transcutaneous auricular vagus nerve stimulation, major depressive disorder, vagus nerve stimulation, sham stimulation, Hamilton Depression Rating Scale, treatment response and remission
MeSH terms
Adult, Major Depressive Disorder, Depressive Disorder, Major, Transcutaneous Electric Nerve Stimulation, Female, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Remission Induction, Self Administration, Cohort Studies, Treatment Outcome, Ear Auricle, Vagus Nerve Stimulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review